Filing Details

Accession Number:
0001622627-25-000002
Form Type:
13G Filing
Publication Date:
2025-02-02 19:00:00
Filed By:
Rosalind Advisors, Inc.
Company:
Cellectar Biosciences Inc. (NASDAQ:CLRB)
Filing Date:
2025-02-03
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Rosalind Advisors, Inc. 0 7,472,745 9.9%
SALAMON STEVEN A J 0 7,472,745 9.9%
Aharon Gil 0 7,472,745 9.9%
Rosalind Master Fund L.P. 0 5,592,395 7.7%
Rosalind Opportunities Fund I L.P. 0 1,880,350 2.6%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  This percentage is calculated based upon 65,301,224.00 shares of the Issuer's common stock outstanding as of January 27, 2025, in accordance with Issuer's S1 filed on January 29, 2025, and preferred shares converted by Rosalind Master Fund L.P. However, the securities reported in rows (6), (8), and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers (as defined below), is less than the number of securities reported in rows (6), (8), and (9). Pursuant to the terms of the certificate of designations containing the terms of the Reported Preferred Stock, the Reporting Persons cannot convert the Reported Preferred Stock to the extent the Reporting Persons would beneficially own, after any such conversion, more than 9.99% of the outstanding shares of Common Stock (the Preferred Stock Blockers) and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Preferred Stock or any of the Reported Warrants due to the Blockers. (6) 502,320 shares of Common Stock issuable upon conversion of Preferred Stock 6,970,425 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 502,320 shares of Common Stock issuable upon conversion of Preferred Stock 6,970,425 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 502,320 shares of Common Stock issuable upon conversion of Preferred Stock 6,970,425 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6)502,320 shares of Common Stock issuable upon conversion of Preferred Stock 5,090,075 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 1,880,350 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G


 
Rosalind Advisors, Inc.
 
Signature:Steven Salamon
Name/Title:President
Date:02/03/2025
 
SALAMON STEVEN A J
 
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:02/03/2025
 
Aharon Gil
 
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:02/03/2025
 
Rosalind Master Fund L.P.
 
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:02/03/2025
 
Rosalind Opportunities Fund I L.P.
 
Signature:Steven Salamon
Name/Title:Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)
Date:02/03/2025